A Multi-Centre Clinical Trial to Evaluate a Left-Right Design in Adults With Mild to Moderate Atopic Dermatitis
NCT ID: NCT02103725
Last Updated: 2025-02-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
30 participants
INTERVENTIONAL
2014-04-30
2014-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Explorative Trial Evaluating the Effect of LEO 32731 Cream in Adults With Mild to Moderate Atopic Dermatitis (AD)
NCT02496546
Pimecrolimus and Epidermal Barrier Function
NCT01132079
Efficacy and Safety of Pimecrolimus Cream 1% in Patients (2 to 11 Years Old) With Mild to Moderate Facial Atopic Dermatitis
NCT00130364
A Clinical Trial to Compare Topical Agents in Adults With Mild to Moderate Atopic Dermatitis (AD)
NCT02376049
Effects of Pimecrolimus on Skin Biopsy Ex-plants From Patients With Atopic Dermatitis
NCT00379678
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
pimecrolimus 10 mg/g cream
Active drug
pimecrolimus 10 mg/g cream
Vehicle cream
Placebo drug
Vehicle cream
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
pimecrolimus 10 mg/g cream
Vehicle cream
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 2\. Subject with atopic dermatitis with mild to moderate disease severity
* 3\. Two symmetrical and comparable atopic dermatitis treatment areas
* 4\. Female volunteers of childbearing potential must either be surgically sterile or agree to use a reliable method of contraception
Exclusion Criteria
* 2\. Dark-skinned persons whose skin colour prevents reliable clinical assessments
* 3\. Any permanent (or transient within 28 days prior to dosing) disease that may interfere with the subjects safe participation in the trial, with the subjects ability to participate in the trial or with the clinical assessments
* 4\. Pregnancy or breastfeeding
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
LEO Pharma
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
bioskin GmbH
Hamburg, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Clinical Trials at LEO Pharma
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EXP-1092
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.